Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 18

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

749

Figures (1-1)

Tables (1-5)

Sum=851

Publishing Process of This Article

Item

Count

Browse

Download

Sum=41

Jun 26, 2024 (publication date) through Jul 17, 2024

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Cases

ISSN

2307-8960

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Controlled Trial

World J Clin Cases. Jun 26, 2024; 12(18): 3468-3475
Published online Jun 26, 2024. doi: 10.12998/wjcc.v12.i18.3468

Table 4 Subgroup analysis of serum uric acid level changes

Subgroups	Dapagliflozin group	Placebo group
Age	-1.3 ± 0.7	-0.2 ± 0.6
Sex	-1.2 ± 0.8	-0.1 ± 0.7
Diabetes status	-1.1 ± 0.8	-0.2 ± 0.7
Baseline serum uric acid level	-1.2 ± 0.8	-0.1 ± 0.7
Baseline eGFR	-1.1 ± 0.8	-0.1 ± 0.7

eGFR: Estimated glomerular filtration rate.

Citation: Lin MJ, Zou SB, Zhu BX. Effect of dapagliflozin on uric acid in patients with chronic heart failure and hyperuricemia. World J Clin Cases 2024; 12(18): 3468-3475
URL: https://www.wjgnet.com/2307-8960/full/v12/i18/3468.htm
DOI: https://dx.doi.org/10.12998/wjcc.v12.i18.3468